[go: up one dir, main page]

EA023913B1 - Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния - Google Patents

Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния Download PDF

Info

Publication number
EA023913B1
EA023913B1 EA201101523A EA201101523A EA023913B1 EA 023913 B1 EA023913 B1 EA 023913B1 EA 201101523 A EA201101523 A EA 201101523A EA 201101523 A EA201101523 A EA 201101523A EA 023913 B1 EA023913 B1 EA 023913B1
Authority
EA
Eurasian Patent Office
Prior art keywords
coenzyme
structural element
obesity
agents
oxidative phosphorylation
Prior art date
Application number
EA201101523A
Other languages
English (en)
Other versions
EA201101523A1 (ru
Inventor
Найвен Раджин Нэрейн
Джон Патрик Маккук
Рангапрасад Сарангараджан
Original Assignee
БЕРГ ФАРМА ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БЕРГ ФАРМА ЭлЭлСи filed Critical БЕРГ ФАРМА ЭлЭлСи
Publication of EA201101523A1 publication Critical patent/EA201101523A1/ru
Publication of EA023913B1 publication Critical patent/EA023913B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)

Abstract

Описаны способы и композиции для лечения метаболических нарушений у людей с использованием эпиметаболических переключателей, многоаспектных внутриклеточных молекул или факторов влияния.

Description

(57) Описаны способы и композиции для лечения метаболических нарушений у людей с использованием эпиметаболических переключателей, многоаспектных внутриклеточных молекул или факторов влияния.
023913 Β1

Claims (24)

1. Способ лечения, облегчения симптомов, предотвращения прогрессирования или профилактики ожирения у млекопитающих, включающий введение нуждающемуся в этом млекопитающему терапевтически эффективного количества фармацевтической композиции, содержащей коэнзим 010 или по меньшей мере один структурный элемент коэнзима 010.
2. Способ по п.1, отличающийся тем, что коэнзим 010 или по меньшей мере один структурный элемент коэнзима 010 селективно вызывает в больных клетках млекопитающего переключение клеточного энергетического метаболизма в направлении нормализованного митохондриального окислительного фосфорилирования.
3. Способ по п.2, отличающийся тем, что коэнзим 010 или по меньшей мере один структурный элемент коэнзима 010, по существу, не вызывает в нормальных клетках млекопитающих переключения клеточного энергетического метаболизма в направлении митохондриального окислительного фосфорилирования.
4. Способ по п.1, отличающийся тем, что млекопитающим является человек (или не являющееся человеком млекопитающее).
5. Способ по п.1, отличающийся тем, что ожирение поддается или чувствительно к воздействию коэнзима 010, или его метаболитов, или аналогов.
6. Способ по п.1, отличающийся тем, что ожирение характеризуется дисрегуляцией функции митохондриального окислительного фосфорилирования, что приводит к изменению регуляции генов и/или взаимодействию белок-белок, что способствует или непосредственно приводит к ожирению.
7. Способ по п.1, отличающийся тем, что по меньшей мере один структурный элемент коэнзима 010 включает:
(a) бензохинон или по меньшей мере одну молекулу, которая способствует биосинтезу бензохинонового кольца, и (b) по меньшей мере одну молекулу, которая способствует синтезу и/или присоединению изопреноидных единиц к бензохиноновому кольцу.
8. Способ по п.7, отличающийся тем, что вышеупомянутая по меньшей мере одна молекула, которая способствует биосинтезу бензохинонового кольца, включает в себя Ь-фенилаланин, ОЬ-фенилаланин, Ό-фенилаланин, Ь-тирозин, ПЬ-тирозин, Ό-тирозин, 4-гидроксифенилпируват, 3-метокси-4гидроксиманделат (ванилилмандалата или УМА), ванилиновую кислоту, пиридоксин или пантенол.
9. Способ по п.7, отличающийся тем, что вышеупомянутая по меньшей мере одна молекула, которая способствует синтезу и/или присоединению изопреноидных единиц к бензохиноновому кольцу, включает в себя фенилацетат, 4-гидроксибензоат, мевалоновую кислоту, ацетилглицин, ацетил-СоА или фарнезил.
10. Способ по п.1, отличающийся тем, что по меньшей мере один структурный элемент коэнзима 010 включает:
(a) один или несколько из Ь-фенилаланина, Ь-тирозина и 4-гидроксифенилпирувата;
(b) один или несколько из 4-гидроксибензоата, фенилацетата и бензохинона.
11. Способ по п.1, отличающийся тем, что коэнзим 010 или по меньшей мере один структурный элемент коэнзима 010:
(a) ингибирует экспрессию Вс1-2 и/или стимулирует экспрессию каспазы-3 и/или (b) ингибирует клеточную пролиферацию.
12. Способ по п.1, отличающийся тем, что концентрация коэнзима 010 или по меньшей мере одного структурного элемента коэнзима 010 в тканях человека, подвергающегося лечению, отличается от концентрации в контрольном стандарте ткани человека, находящегося в здоровом или нормальном состоянии.
13. Способ по п.1, отличающийся тем, что форма коэнзима 010 или по меньшей мере одного структурного элемента коэнзима 010, вводимого человеку, отличается от преобладающей формы, находимой в системе кровотока у человека.
14. Способ по п.1, отличающийся тем, что количество фармацевтической композиции, достаточное для лечения ожирения у человека:
a) повышающе регулирует или понижающе регулирует митохондриальное окислительное фосфорилирование или
b) модулирует анаэробное использование глюкозы и/или биосинтез лактата.
15. Способ по п.1, отличающийся тем, что лечение происходит благодаря взаимодействию коэнзима 010 или по меньшей мере одного структурного элемента коэнзима 010 с НОТЧ-альфа или трансальдолазой.
16. Способ по п.1, где метаболическим нарушением является коэнзим 010 или по меньшей мере один структурный элемент коэнзима 010, действующий на окисление в митохондриях бета-клеток, уменьшающий размер адипоцитов и/или контролирующий уровни кортизола.
- 157 023913
17. Способ избирательного усиления митохондриального окислительного фосфорилирования в больных клетках млекопитающих, нуждающихся в лечении ожирения, включающий введение вышеупомянутому млекопитающему терапевтически эффективного количества фармацевтической композиции, содержащей коэнзим ф10 или по меньшей мере один структурный элемент коэнзима φ10, тем самым избирательно усиливая митохондриальное окислительное фосфорилирование в вышеупомянутых больных клетках млекопитающего.
18. Способ по п.17, отличающийся тем, что дополнительно включает:
a) повышающее регулирование экспрессии одного или более генов, выбранных из группы, состоящей из молекул, перечисленных в табл. 2-4, 6-28 и 63-68, имеющих позитивное кратное изменение; и/или понижающее регулирование экспрессии одного или более генов, выбранных из группы, состоящей из молекул, перечисленных в табл. 2-4, 6-28 и 63-68, имеющих негативное кратное изменение; или
b) модулирование экспрессии одного или более генов, выбранных из группы, состоящей из ΗΝΡ4альфа, Вс1-х1, Вс1-х8, ВМР-2, Вс1-2, В1гс6, Вс1-2-Ь11, ХАР, 20 ВКАР, Вах, с-1ип, ВтР, РИМА, сМус, трансальдолазы 1, СОф1, СОф3, СОф6, пренилтрансферазы, 4-гидробензоата, цитозольного фактора нейтрофилов 2, синтазы оксида азота 2А, супероксиддисмутазы 2, УЭЛС, Вах канала, ΆΝΤ, Цитохрома с, комплекса I, комплекса II, комплекса III, комплекса ТО, Рохо 3а, ΏΙ-1, ГОН-1, Ср!1С и Сат киназы II.
19. Способ по п.1, отличающийся тем, что вышеупомянутое лечение, облегчение симптомов, предотвращение прогрессирования или профилактика ожирения приводят к снижению объема талии, снижению содержания внутреннего жира, снижению уровня триглицеридов в плазме натощак или повышению уровня липопротеина высокой плотности натощак.
20. Способ по любому из пп.1, 17-19, отличающийся тем, что дополнительно включает введение дополнительного терапевтического агента.
21. Способ по п.20, отличающийся тем, что дополнительный терапевтически агент выбирается из группы, состоящей из агентов для лечения сахарного диабета, агентов для лечения осложнений диабета, антигиперлипемических агентов, гипотензивных или антигипертензивных агентов, агентов от ожирения, диуретиков, химиотерапевтических агентов, иммунотерапевтических агентов и иммуносупрессоров.
22. Способ уменьшения уровней липидов у пациента, включающий введение пациенту эффективного количества фармацевтической композиции, содержащей коэнзим ф10 или по меньшей мере один структурный элемент коэнзима ф10.
23. Способ лечения, облегчения симптомов, профилактики прогрессирования или предупреждения поддающегося воздействию коэнзима ф10 нарушения у млекопитающих, включающий введение нуждающемуся в этом млекопитающему терапевтически эффективного количества фармацевтической композиции, содержащей коэнзим ф10 или по меньшей мере один структурный элемент коэнзима ф10, где коэнзим ф10 или по меньшей мере один структурный элемент коэнзима ф10 избирательно вызывает в больных клетках млекопитающего переключение клеточного энергетического метаболизма в направлении уровней гликолиза и митохондриального окислительного фосфорилирования, наблюдаемых в нормальных клетках млекопитающих при нормальных физиологических условиях, где нарушением, поддающимся воздействию коэнзима ф10, является ожирение.
24. Способ по п.1, 17, 22 или 23, в котором фармацевтическая композиция содержит от 1 до 25 мас.% коэнзима ф10 или по меньшей мере одного структурного элемента коэнзима ф10.
Фиг. 1
- 158 023913
Фиг. 2
Фиг. 3
EA201101523A 2009-05-11 2010-05-11 Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния EA023913B1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17724509P 2009-05-11 2009-05-11
US17724109P 2009-05-11 2009-05-11
US17724309P 2009-05-11 2009-05-11
US17724409P 2009-05-11 2009-05-11
US17724609P 2009-05-11 2009-05-11
PCT/US2010/034447 WO2010132502A2 (en) 2009-05-11 2010-05-11 Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers

Publications (2)

Publication Number Publication Date
EA201101523A1 EA201101523A1 (ru) 2012-10-30
EA023913B1 true EA023913B1 (ru) 2016-07-29

Family

ID=43085533

Family Applications (5)

Application Number Title Priority Date Filing Date
EA201101519A EA201101519A1 (ru) 2009-05-11 2010-05-11 Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EA201101522A EA201101522A1 (ru) 2009-05-11 2010-05-11 Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
EA201101521A EA034552B1 (ru) 2009-05-11 2010-05-11 Способ лечения или предотвращения прогрессирования онкологических заболеваний
EA201101523A EA023913B1 (ru) 2009-05-11 2010-05-11 Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EA201101520A EA201101520A1 (ru) 2009-05-11 2010-05-11 Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EA201101519A EA201101519A1 (ru) 2009-05-11 2010-05-11 Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EA201101522A EA201101522A1 (ru) 2009-05-11 2010-05-11 Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
EA201101521A EA034552B1 (ru) 2009-05-11 2010-05-11 Способ лечения или предотвращения прогрессирования онкологических заболеваний

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201101520A EA201101520A1 (ru) 2009-05-11 2010-05-11 Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния

Country Status (13)

Country Link
US (15) US20110020312A1 (ru)
EP (5) EP2429513A4 (ru)
JP (13) JP6169846B2 (ru)
KR (7) KR20120060945A (ru)
CN (7) CN102481269B (ru)
AU (9) AU2010247750B2 (ru)
BR (5) BRPI1010576A2 (ru)
CA (5) CA2763336C (ru)
EA (5) EA201101519A1 (ru)
IL (5) IL216296B (ru)
MX (6) MX345044B (ru)
SG (10) SG10201402293SA (ru)
WO (5) WO2010132479A2 (ru)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2680825C (en) * 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
EA201101519A1 (ru) 2009-05-11 2012-10-30 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
DK2544663T3 (en) 2010-03-12 2018-04-16 Berg Llc INTRAVENOUS FORMULATIONS OF COENZYM Q10 (CoQ10) AND PROCEDURES FOR USING IT
RU2013125033A (ru) * 2010-06-30 2014-12-10 Галдерма Ресерч Энд Девелопмент Способ предупреждения или лечения кожной опухоли
SG182016A1 (en) * 2010-12-14 2012-07-30 Univ Singapore Method of detecting resistance to cancer therapy
EP2656076B1 (en) * 2010-12-20 2017-11-01 Cameron K. Tebbi Methods of detecting leukemia/ lymphoma and induction of the same
US9783785B2 (en) 2010-12-20 2017-10-10 Cameron K. Tebbi Screening methods for detection of susceptibility to leukemia and lymphomas
WO2012097276A2 (en) * 2011-01-13 2012-07-19 Expression Pathology, Inc. Bcl-2-like protein 11 srm/mrm assay
EP2670368A4 (en) * 2011-02-03 2015-04-15 Pharmedica Ltd NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
EA201391245A1 (ru) 2011-03-02 2014-05-30 Берг Ллк Интеррогативные клеточные анализы и их применение
RU2453849C1 (ru) * 2011-03-11 2012-06-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ определения метаболитов углеводного обмена в биологических тканях
CN103608323B (zh) 2011-04-04 2016-08-17 博格有限责任公司 治疗中枢神经系统肿瘤的方法
EP2720689A4 (en) * 2011-06-14 2014-11-26 Edison Pharmaceuticals Inc CATÉCHOL DERIVATIVES FOR THE TREATMENT OF OXIDATIVE STRESS DISEASES
JP5932993B2 (ja) 2011-06-17 2016-06-08 バーグ エルエルシー 吸入可能な医薬組成物
CN102453769A (zh) * 2011-12-27 2012-05-16 芮屈生物技术（上海）有限公司 白血病病变前期mRNA水平原位杂交检测试剂盒及检测方法和应用
US9399035B2 (en) 2012-03-06 2016-07-26 The Board Of Trustees Of The University Of Illinois Procaspase 3 activation by combination therapy
MX357392B (es) 2012-04-02 2018-07-06 Berg Llc Ensayos basados en interrogatorios celulares y uso de los mismos.
MX365302B (es) * 2012-04-20 2019-05-29 Horizon Therapeutics Llc Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno.
KR102163948B1 (ko) * 2012-06-01 2020-10-12 버그 엘엘씨 조효소 q10을 이용한 고형 종양의 치료
US20150218638A1 (en) * 2012-09-06 2015-08-06 Hitachi Chemical Co. America, Ltd. Methods for assessment of peptide-specific immunity
CN104797248B (zh) 2012-09-19 2017-10-31 格雷斯珀公司 用于改善脑功能的组合物
WO2014059008A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
EP2906197A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying synergistic cosmetic combinations
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
WO2014144346A1 (en) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Use of inhibitors of mtor to improve vascular functions in apoe4 carriers
EP2976002A1 (en) * 2013-03-19 2016-01-27 The Procter & Gamble Company Method of measuring the metabolic indicators of hair follicles
NZ713868A (en) * 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
WO2014181968A1 (ko) * 2013-05-09 2014-11-13 가톨릭대학교 산학협력단 메트포민과 코엔자임 q10을 유효성분으로 함유하는 면역 질환의 예방 또는 치료용 조성물
JP2016529224A (ja) * 2013-06-26 2016-09-23 レット シンドローム リサーチ トラスト， インコーポレイテッド レット症候群およびその処置
HUE050060T2 (hu) 2013-09-04 2020-11-30 Berg Llc Eljárások rák kezelésére koenzim Q10 folyamatos infúziójával
CN103585619A (zh) * 2013-10-31 2014-02-19 浙江大学 Dj-1蛋白在制备骨肉瘤诊断和治疗产品中的应用
CA2930737C (en) 2013-11-22 2023-02-21 Pharmakea, Inc. Autotaxin inhibitor compounds
WO2015084862A1 (en) * 2013-12-02 2015-06-11 Fu-Shin Yu Compositions and methods to diagnose diabetes and/or to treat negative effects of diabetes
CA2933908C (en) 2013-12-31 2024-01-30 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
WO2015109116A1 (en) * 2014-01-15 2015-07-23 The Regents Of The University Of California Metabolic screening for gestational diabetes
US11203739B2 (en) 2014-04-07 2021-12-21 Memorial Sloan-Kettering Cancer Center Modulating cell proliferation and pluripotency
WO2015157345A2 (en) * 2014-04-07 2015-10-15 Wake Forest University Health Sciences Bioenergetic profiling of circulating blood cells and systems, devices, and methods relating thereto
JP6487031B2 (ja) * 2014-04-17 2019-03-20 イミューノメット セラピューティクス インコーポレイテッド グアニジン化合物、及びその用途
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
EP3828547A1 (en) * 2014-08-26 2021-06-02 Keio University Anti-cancer agent sensitivity-determining marker
AU2015314956A1 (en) 2014-09-11 2017-04-06 Berg Llc Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data
ES2915267T3 (es) 2015-05-27 2022-06-21 Sabre Therapeutics Llc Inhibidores de autotaxina y usos de los mismos
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
EP3387430A4 (en) * 2015-12-11 2019-08-14 Expression Pathology, Inc. SRM / MRM DOSINGS
AU2017364218A1 (en) * 2016-11-25 2019-07-11 Koninklijke Philips N.V. Method to distinguish tumor suppressive FOXO activity from oxidative stress
US20210130291A1 (en) 2016-12-22 2021-05-06 The National Institute for Biotechnology in the Negev Ltd. Methods for treating diabetes using vdac1 inhibitors
AU2017381697B2 (en) 2016-12-23 2020-12-24 Keio University Compositions and methods for the induction of CD8+ T-cells
WO2018213502A1 (en) 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
CN113683699B (zh) * 2017-06-22 2023-04-18 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
JP7209951B2 (ja) * 2017-10-30 2023-01-23 日本メナード化粧品株式会社 白髪予防及び改善剤
EP3710433A4 (en) 2017-11-17 2022-01-12 The Board of Trustees of the University of Illinois CANCER THERAPY BY REMOVAL OF DOUBLE MEK SIGNALING
CA3088505A1 (en) * 2018-02-09 2019-08-15 Keio University Compositions and methods for the induction of cd8+ t-cells
PE20211816A1 (es) 2018-09-25 2021-09-14 Ponce De Leon Health Designated Activity Company Proceso de elaboracion de alfa-cetoglutarato de calcio
SG11202102485TA (en) 2018-10-05 2021-04-29 Univ Illinois Combination therapy for the treatment of uveal melanoma
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
MX2021008797A (es) 2019-01-23 2022-01-31 Regeneron Pharma Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
GB201911095D0 (en) * 2019-08-02 2019-09-18 Randox Laboratories Ltd Biological status classification
WO2021102356A1 (en) 2019-11-20 2021-05-27 Berg Llc Combination therapy of a coenzyme q10 compound and radiation therapy for treatment of glioma
JP2021084891A (ja) * 2019-11-28 2021-06-03 株式会社ノエビア 抗老化剤
CN112924681B (zh) * 2019-12-05 2023-01-17 张曼 尿液krt10蛋白及其多肽片段在正常妊娠中的应用
KR102383788B1 (ko) * 2020-06-12 2022-04-05 이화여자대학교 산학협력단 신체적 스트레스 상태를 평가하는 방법
US20230255912A1 (en) * 2020-07-02 2023-08-17 Ponce De Leon Health Designated Activity Company Compositions and methods for treating crp-mediated diseases
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
EP4267739A1 (en) 2020-12-23 2023-11-01 Regeneron Pharmaceuticals, Inc. Treatment of liver diseases with cell death inducing dffa like effector b (cideb) inhibitors
CA3210480A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
CN114306608B (zh) * 2022-01-04 2024-01-16 上海科技大学 一类适应低氧或缺氧微环境的肿瘤的治疗靶点及其应用
CN116486916B (zh) * 2022-11-03 2024-08-02 杭州联川生物技术股份有限公司 一种单细胞转录组濒死细胞和多细胞过滤方法、介质和设备
CN117347643B (zh) * 2023-12-05 2024-02-06 成都泰莱生物科技有限公司 用于判断肺部结节良恶性的代谢标志物组合及其筛选方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020049176A1 (en) * 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
US20030235812A1 (en) * 1999-04-30 2003-12-25 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
WO2008156654A2 (en) * 2007-06-15 2008-12-24 Massachusetts Institute Of Technology Cytoskeleton modulators for treating metabolic disorders

Family Cites Families (396)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525350A (en) 1975-02-20 1985-06-25 The New England Institute, Inc. Methods of stimulating host defense system with coenzymes Q4 to Q.sub.1
JPS5775916A (en) 1980-10-29 1982-05-12 Nippon Chemiphar Co Ltd Coenzyme q pharmaceutical and its preparation
JPS58113127A (ja) 1981-12-28 1983-07-05 Ajinomoto Co Inc ユビデカレノン含有水性液
IT1157269B (it) 1982-03-19 1987-02-11 Seuref Ag Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica
JPS58201711A (ja) 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4833128A (en) 1984-12-28 1989-05-23 Neil Solomon Dietary supplement
US4824669A (en) 1985-04-11 1989-04-25 Board Of Regents, The University Of Texas System Formulations of coenzyme Q10 for intravenous use
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
JPS62123113A (ja) 1985-11-22 1987-06-04 Green Cross Corp:The ユビデカレノン含有脂肪乳剤
US4843071A (en) 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
JP2600726B2 (ja) 1987-11-30 1997-04-16 大正製薬株式会社 微粒子脂肪乳剤
GB8811410D0 (en) 1988-05-13 1988-06-15 Unilever Plc Treatment of skin disorders
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5015483A (en) * 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
JP2828655B2 (ja) 1989-04-14 1998-11-25 エーザイ株式会社 脂溶性薬物含有水性液
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5962243A (en) 1990-04-18 1999-10-05 Board Of Regents, The University Of Texas System Methods for the identification of farnesyltransferase inhibitors
ATE117665T1 (de) 1990-11-14 1995-02-15 Oreal Amphiphile, nichtionische derivate des glycerins sowie die entsprechenden zwischenprodukte, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
SE502569C2 (sv) 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
US5378461A (en) 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
US6461593B1 (en) 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
WO1993016704A1 (en) 1992-02-24 1993-09-02 East Carolina University Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
US6093706A (en) 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
FR2697841B1 (fr) 1992-11-12 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
AU6156494A (en) 1993-03-08 1994-09-26 Eisai Co. Ltd. Phosphonic acid derivatives
ATE166573T1 (de) 1993-03-24 1998-06-15 Ciba Geigy Ag Verfahren zur herstellung einer liposomendispersion im hochdruckbereich
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
DE4410238A1 (de) 1994-03-25 1995-09-28 Beiersdorf Ag Hautpflegemittel
US20020049422A1 (en) 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
CA2207093A1 (en) 1994-12-06 1996-06-13 Ryan Pharmaceuticals, Inc. Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US6005086A (en) 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
DE19537027A1 (de) 1995-10-05 1997-04-10 Beiersdorf Ag Hautpflegemittel für alte Haut
WO1997014740A1 (en) 1995-10-19 1997-04-24 Receptagen Corporation Discrete-length polyethylene glycols
US5944012A (en) 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
DE19615577A1 (de) 1996-04-19 1997-10-23 Beiersdorf Ag Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
GB9625895D0 (en) 1996-12-13 1997-01-29 Riley Patrick A Novel compound useful as therapeutic agents and assay reagents
US20040228910A1 (en) 1997-02-11 2004-11-18 Mse Pharmazeutika Gmbh Transdermal, oral and intravenous formulations of 2, 3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone
ATE201988T1 (de) 1997-02-11 2001-06-15 Mse Pharmazeutika Gmbh Transdermale, orale und intravenöse zubereitungen von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4- benzochinon
EP1007018B1 (de) * 1997-02-12 2003-10-08 MSE Pharmazeutika GmbH Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon inder behandlung von tinnitus
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6599513B2 (en) 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
EP1009383A1 (en) 1997-09-04 2000-06-21 Biozone Laboratories, Inc. Oral liposomal delivery system
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
KR20010031501A (ko) 1997-10-31 2001-04-16 추후제출 5-알파 환원효소 활성을 조절하는 방법 및 조성물
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6372880B1 (en) 1997-12-25 2002-04-16 Mitsui Chemicals, Inc. Copolymer and process for preparing the same
US6048846A (en) 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
WO1999051097A1 (en) 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
KR100657388B1 (ko) 1998-04-14 2006-12-13 교와 학꼬 고교 가부시키가이샤 미생물에 의한 이소프레노이드 화합물의 제조 방법
US6503523B2 (en) 1998-05-07 2003-01-07 Gs Development A.B. Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones
EP1089714B1 (en) 1998-06-19 2003-03-05 Skyepharma Canada Inc. Processes to generate particles of water-insoluble compounds of up to 2000 nm in size
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
DE19828081C2 (de) 1998-06-24 2000-08-10 Cognis Deutschland Gmbh W/O-Emulsionsgrundlagen
US6623746B1 (en) 1998-07-16 2003-09-23 Cognis Deutschland Gmbh & Co. Kg PIT emulsions, methods of softening paper using the same, and paper substrates treated therewith
WO2000006143A1 (en) 1998-07-27 2000-02-10 Texas Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
WO2000007607A1 (en) 1998-08-04 2000-02-17 Kosbab, John, V. Nutrient and therapeutic compositions for the treatment of cancer
US6417223B1 (en) * 1998-09-23 2002-07-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses therof
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
IT1304406B1 (it) * 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US20050123938A1 (en) 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US20050019268A1 (en) 1999-02-11 2005-01-27 Mse Pharmazeutika Gmbh Spray containing ubiquinone Qn
US20040034107A1 (en) 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6803193B1 (en) 1999-06-23 2004-10-12 The Penn State Research Foundation Methods to identify modulators of the mevalonate pathway in sterol synthesis
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
DE59912559D1 (de) * 1999-07-02 2005-10-20 Cognis Ip Man Gmbh Mikrokapseln - III
US6630160B1 (en) 1999-09-07 2003-10-07 Genetic Services Management, Inc. Process to modulate disease risk with doses of a nutraceutical
US20030104080A1 (en) 1999-09-07 2003-06-05 Singh Parashu Ram Topical urea composition
US7005274B1 (en) 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
AU768306B2 (en) 1999-10-14 2003-12-04 Nisshin Oil Mills, Ltd., The Skin-care agents, skin antiaging agents, whitening agents and external skin preparations
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7083780B2 (en) 1999-12-11 2006-08-01 Cognis Deutschland Gmbh & Co. Kg Cosmetic composition containing hydroxyethers
EP1239826A2 (de) 1999-12-20 2002-09-18 Cognis France S.A. Kosmetische und/oder pharmazeutische zubereitungen
AUPQ515000A0 (en) 2000-01-19 2000-02-10 Grigg, Geoffrey Walter Treatment of uv induced immunosuppression
AU776851B2 (en) 2000-02-04 2004-09-23 Takeda Pharmaceutical Company Limited Stable emulsion compositions
GB2360706B (en) 2000-02-09 2002-07-17 Paul A Sneed Treatment of fibromyalgia with ubiquinone 10 and succinic acid
US20020044913A1 (en) 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
FR2804864B1 (fr) 2000-02-11 2003-04-04 Serobiologiques Lab Sa Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie
DE10007322A1 (de) * 2000-02-17 2001-08-23 Cognis Deutschland Gmbh Perlglanzmittel
DE50115609D1 (de) 2000-02-17 2010-10-14 Basf Se Wässrige Dispersion wasserunlöslicher organischer UV-Filtersubstanzen
FR2805464B1 (fr) 2000-02-25 2003-02-14 Serobiologiques Lab Sa Preparations cosmetiques contenant des extraits de la plante mourera fluviatilis
DE10009996B4 (de) 2000-03-02 2005-10-13 Cognis Ip Management Gmbh Feststoffgranulate mit monodisperser Korngrößenverteilung, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
US6866864B2 (en) 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
RU2251405C2 (ru) 2000-03-27 2005-05-10 Шотт Глас Композиции для косметических препаратов, средств личной гигиены, компонентов очищающего действия, пищевых добавок, способы их получения и применения
US6447760B2 (en) 2000-05-08 2002-09-10 Playtex Products, Inc. Sunless tanning compositions
CN100500140C (zh) 2000-05-09 2009-06-17 钟渊化学工业株式会社 含有作为活性成分的辅酶q的皮肤组合物
US6468552B1 (en) 2000-06-02 2002-10-22 Neutrogena Corporation Stabilized compositions containing oxygen-labile active agents
SE0002189D0 (sv) * 2000-06-09 2000-06-09 Metcon Medicin Ab New method and assay
DE10031703A1 (de) 2000-06-29 2002-01-10 Beiersdorf Ag Verwendung von Calcium freisetzenden oder bindenden Substanzen zur gezielten Schächung oder Stärkung der Barrierefunktion der Haut
EP1170015A1 (de) 2000-07-06 2002-01-09 Laboratoires Serobiologiques(Societe Anonyme) Verwendung von Extrakten des Pilzes Grifola frondosa
DE10033022A1 (de) * 2000-07-07 2002-01-17 Cognis Deutschland Gmbh Aerosole
US20030012825A1 (en) 2000-07-10 2003-01-16 Charles Kapper Metallized molecule therapies
US6465517B1 (en) 2000-07-11 2002-10-15 N.V. Nutricia Composition for the treatment of migraine
DE10034619A1 (de) 2000-07-17 2002-01-31 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
DE10036655A1 (de) 2000-07-26 2002-02-07 Basf Ag Kosmetische oder dermatologische Zubereitungen zur Vermeidung von Hautschädigungen durch Peroxide
DE10036799A1 (de) 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20020045230A1 (en) 2000-08-14 2002-04-18 Rosen Craig A. Nucleic acids, proteins, and antibodies
FR2813195B1 (fr) 2000-08-29 2003-04-04 Serobiologiques Lab Sa Utilisation d'extraits de la plante cassia alata dans des produits de soin
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
DE10048260A1 (de) 2000-09-29 2002-04-11 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE10053328A1 (de) * 2000-10-27 2002-05-08 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6689385B2 (en) 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
US6403116B1 (en) 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
IT1317938B1 (it) 2000-11-17 2003-07-15 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di alterazioni delmetabolismo lipidico, delle forme allergiche e per attivare le difese
US20070003536A1 (en) 2000-11-21 2007-01-04 Zimmerman Amy C Topical skin compositions, their preparation, and their use
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
WO2002047493A2 (en) 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Health promoting compositions
DE10064818A1 (de) 2000-12-22 2002-06-27 Basf Ag Verwendung von Chroman-Derivaten in kosmetischen oder dermatologischen Zubreitungen
US6806069B2 (en) * 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
FR2819414A1 (fr) 2001-01-15 2002-07-19 Cognis France Sa Preparations cosmetiques et/ou pharmaceutiques comprenant des extraits de plantes dites a resurrection
AU2002226650A1 (en) 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
EP1353667A1 (en) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
NL1017205C2 (nl) 2001-01-26 2002-07-29 Adriaan Emanuel Hendricus Wiel Medicinale en cosmetische toepassing van hop en co-enzym Q10.
ITRM20010044A1 (it) * 2001-01-29 2002-07-29 Sigma Tau Healthscience Spa Integratore alimentare ad effetto dimagrante.
IL157145A0 (en) 2001-01-31 2004-02-08 Idec Pharma Corp Use of dc23 antagonists for the treatment of neoplastic disorders
ITMI20010204A1 (it) 2001-02-02 2002-08-02 Hunza Di Marazzita Maria Carme Specialita' terapeutiche dotate di attivita' antiossidante ed in grado di controllare l'eccesso del peso corporeo
FR2821624B1 (fr) 2001-03-01 2004-01-02 Sod Conseils Rech Applic Nouveau polynucleotide utilisable pour moduler la proliferation des cellules cancereuses
WO2002071874A2 (en) 2001-03-09 2002-09-19 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
DE10113046A1 (de) 2001-03-15 2002-09-26 Beiersdorf Ag Selbstschäumende schaumförmige Zubereitungen mit organischen Hydrokolliden und partikulären hydrophobisierten und/oder ölabsorbierenden Festkörpersubstanzen
DE10113050A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen organischen Hydrokolloiden
DE10113053A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen mit anorganischen Gelbildnern und organischen Hydrololloiden
EP1243252B1 (fr) 2001-03-23 2006-05-24 L'oreal Composition pour le peau, contenant des fibres et des ubiquinones
US20030031688A1 (en) 2001-04-02 2003-02-13 Dipak Ghosh Cosmetic composition with improved skin moisturizing properties
US6727234B2 (en) 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
US6469061B1 (en) 2001-04-04 2002-10-22 Ramot University Authority For Applied Research And Industrial Development Limited Jasmonate pharmaceutical composition for treatment of cancer
DE10118269A1 (de) 2001-04-12 2002-10-17 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6686485B2 (en) * 2001-04-19 2004-02-03 Daniel David West Synthesis of coenzyme Q10, ubiquinone
WO2002085297A2 (en) 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
US20040049022A1 (en) 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
US20070021360A1 (en) 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
US6582723B2 (en) 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
JP3742602B2 (ja) 2001-05-09 2006-02-08 株式会社カネカ 還元型補酵素ｑの安定な溶液
JP4603192B2 (ja) 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
KR20060103288A (ko) 2001-05-10 2006-09-28 카네카 코포레이션 활성 성분으로 조효소 ｑ를 함유하는 경점막 투여용 조성물
GB0111279D0 (en) 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
DE10123771B4 (de) 2001-05-16 2019-01-10 Beiersdorf Ag Verwendung von Elektrolyten zur Stärkung der Barrierefunktion der Haut
EP1260212A1 (de) 2001-05-21 2002-11-27 Cognis France S.A. Kosmetische Mittel
US20050118151A1 (en) 2001-05-29 2005-06-02 Syddansk Universitet Proteins in diabetes proteome anlysis
RU2003133142A (ru) 2001-05-30 2005-04-20 Лэксдейл Лимитед (GB) Коэнзим q и эйкозапентаеновая кислота (эпк)
US20030138792A1 (en) 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
EP1262167A1 (de) 2001-06-01 2002-12-04 Cognis France S.A. Kosmetische Zubereitungen enthaltend ein Extrakt von keimenden Pflanzen
US6696060B2 (en) 2001-06-14 2004-02-24 Clearant, Inc. Methods for sterilizing preparations of monoclonal immunoglobulins
US6506915B1 (en) 2001-06-14 2003-01-14 Daniel David West Synthesis of coenzyme Q10 ubiquinone
FR2826017B1 (fr) 2001-06-15 2004-06-11 Cognis France Sa Melanges de tensioactifs
SE0102380D0 (sv) 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
DE10133198A1 (de) 2001-07-07 2003-01-23 Beiersdorf Ag Kreatin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
CA2453362A1 (en) 2001-07-10 2003-01-23 Oligos Etc. Inc. Oligonucleotide-containing pharmacological compositions and their use
JP2003020495A (ja) 2001-07-10 2003-01-24 Cognis Japan Ltd 油脂組成物
CH695085A5 (de) 2001-07-13 2005-12-15 Mibelle Ag Cosmetics Formulierungen zur Pflege der Haut nach Laserbehandlungen und/oder chemischen Peelings und Verwendung der Formulierungen.
TWI235146B (en) 2001-07-16 2005-07-01 Kaneka Corp Method of stabilizing reduced coenzyme q10 and method of acidic crystallization
EP1414471B1 (en) 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
FR2827603B1 (fr) 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
WO2003009704A2 (en) 2001-07-27 2003-02-06 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
EP1281392A1 (de) 2001-08-02 2003-02-05 Cognis France S.A. Kosmetische und/oder pharmaceutische Zubereitungen enthaltend Pflanzenextrakte
DE10139580A1 (de) * 2001-08-10 2003-02-20 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen mit einem Gehalt an Sterinen und/oder C12-C40-Fettsäuren
US6503506B1 (en) 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
DE10143962A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
DE10143964A1 (de) 2001-09-07 2003-03-27 Basf Ag Emulgatorarme oder emulgatorfreie Systeme vom Typ Öl-in-Wasser mit einem Gehalt an Stabilisatoren und einem aminosubstituierten Hydroxybenzophenon
DE10143963A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von W/O-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
US7425320B2 (en) 2001-09-18 2008-09-16 Ciba Specialty Chemicals Corp Use of guaiol for treating the skin
DE10150725A1 (de) * 2001-10-13 2003-04-17 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
US7247714B2 (en) 2001-10-16 2007-07-24 Atherogenics, Inc. Protection against oxidative stress and inflammation by a cytoprotective response element
US7560123B2 (en) 2004-08-12 2009-07-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20060039956A1 (en) * 2001-10-26 2006-02-23 Hermann Hensen Impregnating solution for cosmetic cloths
US6723527B2 (en) 2001-10-26 2004-04-20 Board Of Regents, The University Of Texas System Methods for determining toxicity reversing agents
CN100343238C (zh) 2001-11-03 2007-10-17 阿斯特拉曾尼卡有限公司 用作抗肿瘤药物的喹唑啉衍生物
US7435725B2 (en) 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US6753325B2 (en) 2001-11-06 2004-06-22 The Quigley Corporation Composition and method for prevention, reduction and treatment of radiation dermatitis
US20030118536A1 (en) 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
US20030105027A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US20030105031A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
ATE436017T1 (de) * 2001-11-09 2009-07-15 Medstar Res Inst Verfahren zur verwendung physiologischer marker für die abschätzung eines herz-kreislauf-risikos
DE10155769A1 (de) * 2001-11-14 2003-05-22 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
DE10160682A1 (de) * 2001-12-11 2003-06-18 Cognis Deutschland Gmbh Emollients und kosmetische Zusammensetzungen
US6652891B2 (en) 2001-12-12 2003-11-25 Herbasway Laboratories, Llc Co-enzyme Q10 dietary supplement
DE10162026A1 (de) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Hochkonzentriert fließfähige Perlglanzkonzentrate
DE10162351A1 (de) * 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
TWI349039B (en) 2001-12-27 2011-09-21 Kaneka Corp Processes for producing coenzyme q10
US20030129253A1 (en) * 2002-01-03 2003-07-10 Milley Christopher J. Stable aqueous suspension
TW200302056A (en) 2002-01-18 2003-08-01 Kaneka Corp Method for stabilizing reduced coenzyme Q10 and composition therefor
EP1469822A2 (de) 2002-01-18 2004-10-27 Basf Aktiengesellschaft Kosmetische oder dermatologische zubereitungen, enthaltend bor-organische verbindungen, zur vermei dung von hautschädigungen durch peroxide
CN100473374C (zh) 2002-01-31 2009-04-01 西巴特殊化学品控股有限公司 微粉颜料混合物
KR100969059B1 (ko) 2002-02-12 2010-07-09 디에스엠 아이피 어셋츠 비.브이. 다이하이드로피리딘, 다이하이드로피란 및 일광차단 조성물
ATE392152T1 (de) 2002-02-14 2008-05-15 Dsm Ip Assets Bv Coenzym q10 formulierungen
EP1340486A1 (de) 2002-03-01 2003-09-03 Cognis France S.A. Verwendung von Zuckerestern
US20030167556A1 (en) 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
DE10254315A1 (de) 2002-03-15 2003-10-02 Cognis Deutschland Gmbh Emollients und kosmetische Zubereitungen
EP2071338A3 (en) 2002-03-20 2009-07-22 Pride Proteomics A/S Human diabetes-mediating proteins
TW200304372A (en) * 2002-03-20 2003-10-01 Kanegafuchi Chemical Ind Compositions for diabetes
DE10212528A1 (de) * 2002-03-21 2003-10-02 Cognis Deutschland Gmbh Ölphasen für kosmetische Mittel
DE10213957A1 (de) * 2002-03-28 2003-10-09 Beiersdorf Ag Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren
US7811594B2 (en) * 2002-03-28 2010-10-12 Beiersdorf Ag Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions
DE10217474A1 (de) 2002-04-19 2003-11-06 Cognis Deutschland Gmbh Sonnenschutzemulsion mit Schaumspender
US20060193905A1 (en) 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
US7939098B2 (en) 2002-05-23 2011-05-10 Femina Pharma Incorporated Compositions and method for transmucosal drug delivery and cryoprotection
DE10223486A1 (de) * 2002-05-27 2003-12-11 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen
EP1371355B1 (en) 2002-06-03 2006-08-02 Ciba SC Holding AG UV-protection formulations
DE10226018A1 (de) 2002-06-12 2003-12-24 Cognis Deutschland Gmbh Zubereitungen mit konjugiertem Linolalkohol
US7182950B2 (en) 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
US7147841B2 (en) 2002-06-17 2006-12-12 Ciba Specialty Chemicals Corporation Formulation of UV absorbers by incorporation in solid lipid nanoparticles
AU2003246592A1 (en) 2002-06-26 2004-01-19 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
US7060733B2 (en) 2002-08-15 2006-06-13 The Regents Of The University Of California Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
US20060205771A1 (en) 2002-09-25 2006-09-14 Mark Noble Caspase inhibitors as anticancer agents
US6953786B2 (en) 2002-10-01 2005-10-11 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
FR2845602B1 (fr) 2002-10-11 2005-07-08 Servier Lab Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
EP1421929A3 (de) 2002-11-21 2004-11-24 Cognis Deutschland GmbH & Co. KG Emollients und kosmetische Zubereitungen
DE10256881A1 (de) 2002-12-05 2004-06-24 Beiersdorf Ag Neue topische Verwendung von Bis-Arylimidazo[1,2-a]thiolanderivaten
US20040110848A1 (en) 2002-12-10 2004-06-10 Peffley Dennis M Method and kit for treating cancer
WO2004055181A1 (en) 2002-12-16 2004-07-01 Garvan Institute Of Medical Research Methods of treatment of feeding disorders or disorders of glucose uptake and for modifying metabolism and identifying therapeutic reagents therefor
CA2511501A1 (en) 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
EP2826484A1 (en) 2003-01-02 2015-01-21 Gerard M. Housey IRS modulators
US20090036516A1 (en) 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
US8187575B2 (en) 2003-01-20 2012-05-29 BASF SE Ludwigshafen Triazine derivatives as UV absorbers
US20060073106A1 (en) * 2003-02-03 2006-04-06 Dsm Ip Assets B.V. Novel stabilized cinnamic ester sunscreen compositions
US7258876B2 (en) 2003-02-05 2007-08-21 Craig Bozzacco Topical composition for treating infectious conditions of skin and mucosa
CN1208052C (zh) 2003-03-20 2005-06-29 上海家化联合股份有限公司 一种辅酶q10前体脂质体及其制备方法
KR101187002B1 (ko) 2003-03-24 2012-09-28 시바 홀딩 인코포레이티드 대칭 트리아진 유도체
CA2521149C (en) 2003-04-08 2014-03-25 Barrie Tan Annatto extract compositions, including geranyl geraniols and methods of use
US20050037102A1 (en) 2003-07-18 2005-02-17 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
JP2004321171A (ja) 2003-04-11 2004-11-18 Fancl Corp 飲食品
EP1473043A1 (en) 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
JP2004345988A (ja) * 2003-05-21 2004-12-09 Eisai Co Ltd リボフラビン系化合物を含む医薬組成物
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20040253323A1 (en) 2003-06-11 2004-12-16 Giles Brian C. Ionic cancer therapy and methods for using same in the treatment of tumors and metastasis
US8003094B2 (en) 2003-06-25 2011-08-23 Charles Erwin Chemical combination and method for increasing delivery of Coenzyme Q10
US20050026879A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US8802161B2 (en) 2003-08-02 2014-08-12 Florida Agricultural And Mechanical University Herbal composition and method of use for the treatment of cancer
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US20070248693A1 (en) 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20050036976A1 (en) 2003-08-12 2005-02-17 Joel Rubin Topical skin care composition
WO2005020940A1 (de) 2003-08-27 2005-03-10 Beiersdorf Ag Kapsel deren kapselhülle bei topischer anwendung nicht mehr gesondert warhnembar ist
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) * 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
BRPI0414858A (pt) 2003-10-02 2006-11-21 Sembiosys Genetics Inc métodos para preparação de corpos de óleo compreendendo ingredientes ativos
DE10347218A1 (de) * 2003-10-10 2005-05-12 Cognis Deutschland Gmbh Sonnenschutzmittel
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
DE10347940A1 (de) 2003-10-15 2005-05-19 Cognis Deutschland Gmbh & Co. Kg Selbstemulgierende Zubereitungen
JP4732898B2 (ja) 2003-10-31 2011-07-27 株式会社カネカ 還元型補酵素ｑ含有組成物
AU2004290493B2 (en) 2003-11-05 2009-09-24 Dsm Ip Assets B.V. Light protecting composition with reduced total amount of UV filter containing a polysiloxane-based UV filter
US20050100537A1 (en) 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
WO2005048925A2 (en) 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
DE20320413U1 (de) 2003-11-17 2004-08-26 Beiersdorf Ag Kosmetikum mit empfindlichen Inhaltsstoffen
US20050118235A1 (en) 2003-12-02 2005-06-02 Shiguang Yu Dietary non-essential amino acid tyrosine regulates the body weight of animals through regulating the animal appetite or food intake
ES2658344T3 (es) 2003-12-18 2018-03-09 Nestec S.A. Composición que contiene flavononas, para la mejora de la salud de la piel y del pelo, y del pelaje
JP4742526B2 (ja) * 2003-12-26 2011-08-10 シンフォニアテクノロジー株式会社 Ｉｃチップ実装体の製造方法及び製造装置
CA3031283A1 (en) 2004-01-22 2005-08-04 University Of Miami Topical co-enzyme q10 formulations and methods of use
US20050226947A1 (en) 2004-02-04 2005-10-13 Dale Kern Agents for sequestering serum aging factors and uses therefore
US20070149618A1 (en) 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
NZ549159A (en) * 2004-02-19 2011-01-28 Chemaphor Inc Topical formulations for the treatment of skin conditions
EP1718163A1 (en) 2004-02-23 2006-11-08 The Texas A&M University System Antioxidant compositions and methods of use thereof
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
US20050202521A1 (en) 2004-03-10 2005-09-15 Albert Crum Methods of assessing the need for and the effectiveness of therapy with antioxidants
DE102004014615A1 (de) 2004-03-23 2005-10-13 Beiersdorf Ag Taurinhaltige Zubereitungen zur Verbesserung der Hautbarriere
US7182938B2 (en) 2004-04-06 2007-02-27 Basf Aktiengesellschaft Cosmetic formulations comprising ZnO nanoparticles
US20050226858A1 (en) 2004-04-09 2005-10-13 Kaneka Corporation Compositions containing reduced coenzyme Q10 and carotenoid
US7723569B2 (en) * 2004-04-30 2010-05-25 National Institute Of Agrobiological Sciences Method for producing ubiquinone-10 in plant
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
IL161899A0 (en) 2004-05-10 2005-11-20 Hoffman Arnold Kit for treatment of cancer
JP2005323573A (ja) * 2004-05-17 2005-11-24 Sumitomo Pharmaceut Co Ltd 遺伝子発現データ解析方法および、疾患マーカー遺伝子の選抜法とその利用
US20070202090A1 (en) 2004-05-18 2007-08-30 Mirko Prosek Water Soluble Form Of Coenzyme Q10 In The Form Of An Inclusion Complex With Beta-Cyclodextrin, Process Of Preparing, And Use Thereof
NZ551366A (en) 2004-05-24 2009-01-31 Basf Ag Keratin-binding polypeptides
KR20050112942A (ko) 2004-05-28 2005-12-01 주식회사 뉴트렉스테크놀러지 비만 억제용 조성물
US20050288333A1 (en) 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
CA2578709C (en) 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
WO2005123101A1 (en) 2004-06-18 2005-12-29 Symrise Gmbh & Co. Kg Blackberry extract
AU2005265155A1 (en) 2004-06-21 2006-01-26 Hutchison Medipharma Enterprises Limited Cancer chemotherapy
ES2380940T3 (es) 2004-06-28 2012-05-21 Dsm Ip Assets B.V. Composiciones cosméticas que contienen hidrolizados de proteína
WO2006005759A2 (en) 2004-07-13 2006-01-19 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
US20060069068A1 (en) 2004-07-15 2006-03-30 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by pathological calcification
AU2005269382A1 (en) 2004-07-28 2006-02-09 Raymond M. Pleva Emu oil and fruit composition
JP2006070016A (ja) 2004-08-02 2006-03-16 Kaneka Corp 還元型補酵素ｑを含有する美白用組成物
WO2006017494A2 (en) * 2004-08-02 2006-02-16 Elizabeth Mazzio Inhibition of anaerobic glucose metabolism
ZA200702216B (en) 2004-08-18 2008-11-26 Ace Aps Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists
WO2006023342A2 (en) 2004-08-20 2006-03-02 Tishcon Corp Synergistic conjugated linoleic acid (cla) and carnitine combination
US20060051462A1 (en) 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
US7288263B2 (en) * 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
CN101102768A (zh) 2004-09-17 2008-01-09 中国医学科学院医药生物技术研究所 治疗高脂血症的方法和组合物
US20060062755A1 (en) 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
JP5093998B2 (ja) 2004-09-22 2012-12-12 大塚製薬株式会社 色素沈着予防又は改善剤
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
CA2581764A1 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Minicapsule formulations
EP1809272A4 (en) 2004-10-18 2008-01-02 Maroon Biotech Corp METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS
WO2006050155A2 (en) 2004-10-29 2006-05-11 Biomune, Inc. Cancer therapeutic compositions
BRPI0517930A (pt) * 2004-11-02 2008-10-21 Dsm Ip Assets Bv aditivo para preparações de protetor solar contra uv
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
GB0424891D0 (en) 2004-11-11 2004-12-15 Boots Co Plc Topical compositions
CN101119710B (zh) * 2004-11-16 2013-03-27 生物利用股份有限公司 用于营养用途的高浓度自微乳化辅酶q10制剂
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20060127384A1 (en) 2004-12-09 2006-06-15 Sergio Capaccioli Coenzyme Q10 as antiapoptotic agent
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
CA2589135A1 (en) * 2004-12-14 2006-06-22 F. Hoffmann-La Roche Ag Cd99 as target/marker for insulin resistance
WO2006063402A1 (en) 2004-12-16 2006-06-22 Melvin Mackenzie Stewart Therapeutic compositions based on extracts of plants from the genus plumeria (frangipani)
NO20045674D0 (no) * 2004-12-28 2004-12-28 Uni I Oslo Thin films prepared with gas phase deposition technique
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
US20060188492A1 (en) 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
DE102005007980A1 (de) 2005-02-22 2006-02-23 Clariant Gmbh Kosmetische, pharmazeutische oder dermatologische Zubereitungen enthaltend Copolymerwachse
WO2006103750A1 (ja) 2005-03-29 2006-10-05 Nippon Meat Packers, Inc. 肥満改善用組成物、機能性食品及び医薬用組成物
EP1871389A2 (en) 2005-04-01 2008-01-02 Zymes, LLC Skin enrichment using coq10 as the delivery system
CN1853507A (zh) * 2005-04-28 2006-11-01 尚宝虎 一种没有副作用的可用于饮料和固体口服制剂或食品添加的减肥新组方
JP2007001922A (ja) * 2005-06-23 2007-01-11 Asahi Kasei Pharma Kk 透析患者における腎疾患改善剤、又は機能性食品
US20100150894A1 (en) 2005-07-28 2010-06-17 Kaneka Corporation Composition for prevention of cancer
US20070026072A1 (en) 2005-07-28 2007-02-01 Stephen Olsen Benzoquinones of enhanced bioavailability
US20070053985A1 (en) 2005-08-24 2007-03-08 Kaneka Corporation Coenzyme Q10-containing fine particle with excellent dispersibility
CN1928556A (zh) * 2005-09-05 2007-03-14 中国医学科学院基础医学研究所 中国人2型糖尿病血清标志物的检测试剂盒
US20070071779A1 (en) 2005-09-26 2007-03-29 Leggit Ingenuity, Llc Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof
EP1876448A1 (en) * 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
US20070092469A1 (en) * 2005-10-26 2007-04-26 Eric Jacobs Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE)
US8506956B2 (en) * 2005-10-31 2013-08-13 Kaneka Corporation Method for stabilizing reduced coenzyme Q10
US9265792B2 (en) * 2005-11-16 2016-02-23 Patricia A. Riley Integument cell regeneration formulation
WO2007072225A2 (en) 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1957109A2 (en) 2005-12-02 2008-08-20 Sirtris Pharmaceuticals, Inc. Modulators of cdc2-like kinases (clks) and methods of use thereof
JP2007176804A (ja) * 2005-12-27 2007-07-12 Ｚｍｃ−Ｋｏｕｇｅｎ株式会社 痩身作用を有する医薬又は健康食品
US20070172436A1 (en) 2006-01-23 2007-07-26 Jerry Zhang Nonaqueous ascorbic acid compositions and methods for preparing same
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
US20070184041A1 (en) 2006-02-09 2007-08-09 Burja Adam M Methods and compositions related to production of coenzyme q10
CA2642342A1 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8067152B2 (en) 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers
US20070203091A1 (en) 2006-02-28 2007-08-30 Eliezer Rapaport Methods and therapeutic compositions for improving liver, blood flow and skeletal muscle functions in advanced diseases and aging
DK1993515T3 (da) 2006-03-10 2009-12-07 Laboswiss Ag Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme
US7335384B2 (en) 2006-03-17 2008-02-26 4K Nutripharma International Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
US8030013B2 (en) 2006-04-14 2011-10-04 Mount Sinai School Of Medicine Methods and compositions for the diagnosis for early hepatocellular carcinoma
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
WO2007126086A1 (ja) 2006-04-28 2007-11-08 Kaneka Corporation 還元型補酵素ｑ10の精製方法
US7829080B2 (en) 2006-04-28 2010-11-09 Kaneka Corporation Stabilization method of reduced coenzyme Q10
EP3173068B1 (en) 2006-05-02 2020-09-09 University of Miami Topical co-enzyme q10 formulations and treatment of wounds
WO2007142347A1 (ja) 2006-06-05 2007-12-13 Shimadzu Corporation 腫瘍マーカー及び癌疾病の罹患の識別方法
US20080020022A1 (en) * 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
US20080014187A1 (en) * 2006-07-15 2008-01-17 Bryant Villeponteau Compositions and Methods for Treating Hypertension and Inflammation
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
CN101522609A (zh) 2006-09-05 2009-09-02 彼帕科学公司 癌症的治疗
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
US20080138326A1 (en) 2006-12-06 2008-06-12 Kaneka Corporation Method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agents
CN101015524B (zh) * 2007-02-15 2011-09-14 沈阳药科大学 辅酶q10口服乳剂及其制备方法
CA2680825C (en) * 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
US20090005398A1 (en) 2007-06-27 2009-01-01 Mohammed Dar Methods For The Treatment of Central Nervous System Tumors
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
KR100849537B1 (ko) 2007-07-04 2008-07-31 유효경 코엔자임 큐텐의 나노에멀젼 조성물
JP5701601B2 (ja) 2007-07-17 2015-04-15 メタボロン インコーポレイテッド 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法
CN101091890A (zh) 2007-07-26 2007-12-26 沈阳药科大学 一种复合型乳化剂及用其制备的乳剂及其制备方法
US7776894B2 (en) 2007-08-17 2010-08-17 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
RU2345367C1 (ru) 2007-08-22 2009-01-27 Государственное образовательное учреждение высшего профессионального образования Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО НГМУ Росздрава) Способ прогнозирования тяжести течения и эффективности лечения лимфом
JP2009050168A (ja) * 2007-08-23 2009-03-12 Tsujido Kagaku Kk 食品組成物
WO2009040426A1 (en) 2007-09-28 2009-04-02 Universitätsspital Basel Immunoliposomes for treatment of cancer
JP2009096757A (ja) * 2007-10-17 2009-05-07 Tsujido Kagaku Kk 脂肪代謝抑制剤
US20110142914A1 (en) 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
US20110136231A1 (en) 2008-04-11 2011-06-09 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
JP5945096B2 (ja) 2008-07-04 2016-07-05 小野薬品工業株式会社 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
CA2743255C (en) 2008-12-03 2014-02-18 Andrew Pecora Infarct area perfusion-improving compositions and methods of vascular injury repair
DE102008060773A1 (de) 2008-12-05 2010-06-10 Sartorius Stedim Biotech Gmbh Verschluss für einen Behälter
US8247435B2 (en) 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
EA201101519A1 (ru) 2009-05-11 2012-10-30 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
MX2012002208A (es) 2009-08-25 2012-06-12 Cytotech Labs Llc Metodos para el tratamiento de un sarcoma empleando un cambiador epimetabolico (coenzima q10).
US8506954B2 (en) 2009-12-01 2013-08-13 The Board Of Trustees Of The Leland Stanford Junior University Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy
DK2544663T3 (en) 2010-03-12 2018-04-16 Berg Llc INTRAVENOUS FORMULATIONS OF COENZYM Q10 (CoQ10) AND PROCEDURES FOR USING IT
CA3101711C (en) 2010-07-19 2024-02-13 Biogen Chesapeake Llc Methods of intravenous administration of glyburide and other drugs
US9125835B2 (en) 2010-11-12 2015-09-08 Rutgers, The State University Of New Jersey Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases
CN103429264A (zh) 2011-03-31 2013-12-04 默沙东公司 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
CN103608323B (zh) 2011-04-04 2016-08-17 博格有限责任公司 治疗中枢神经系统肿瘤的方法
CA2869475A1 (en) 2012-04-03 2013-11-14 Quizcamp-Fabrico E Comercio De Produtos Alimentares, S.A. Modular integrated system for seed germination, cultivation, planting, fertilizing and maintenance of plants
KR102163948B1 (ko) 2012-06-01 2020-10-12 버그 엘엘씨 조효소 q10을 이용한 고형 종양의 치료
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
HUE050060T2 (hu) 2013-09-04 2020-11-30 Berg Llc Eljárások rák kezelésére koenzim Q10 folyamatos infúziójával
JP6398212B2 (ja) 2014-02-12 2018-10-03 株式会社Ihi 軸受構造、および、過給機
CA2962255A1 (en) 2014-10-03 2016-04-07 The Board Of Trustees Of The Leland Stanford Junior University Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response
CA2965034C (en) 2014-10-24 2023-05-02 Astrazeneca Ab Combination of an immunomodulatory agent and an antisense oligonucleotide
WO2016094639A1 (en) 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20180021270A1 (en) 2016-07-21 2018-01-25 Berg Llc Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
US10373477B1 (en) 2016-09-28 2019-08-06 Gojo Industries, Inc. Hygiene compliance modules for dispensers, dispensers and compliance monitoring systems
JP6895250B2 (ja) 2016-12-28 2021-06-30 日東電工株式会社 表面保護フィルム
CN116236688A (zh) 2018-07-03 2023-06-09 埃德温·阊 使用交变电场提高细胞膜通透性
WO2020081601A1 (en) 2018-10-15 2020-04-23 Berg Llc Methods of treating pancreatic cancer using coenzyme q10
WO2021102356A1 (en) 2019-11-20 2021-05-27 Berg Llc Combination therapy of a coenzyme q10 compound and radiation therapy for treatment of glioma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235812A1 (en) * 1999-04-30 2003-12-25 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
US20020049176A1 (en) * 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
WO2008156654A2 (en) * 2007-06-15 2008-12-24 Massachusetts Institute Of Technology Cytoskeleton modulators for treating metabolic disorders

Also Published As

Publication number Publication date
BRPI1011025A8 (pt) 2016-07-19
BRPI1010576A2 (pt) 2016-03-15
US20210332439A1 (en) 2021-10-28
US12209285B2 (en) 2025-01-28
AU2016222515A1 (en) 2016-09-22
US20180355435A1 (en) 2018-12-13
JP6254979B2 (ja) 2017-12-27
KR20120034647A (ko) 2012-04-12
MX2011011949A (es) 2012-02-13
AU2016204621A1 (en) 2016-07-21
CN102481270A (zh) 2012-05-30
JP2017214413A (ja) 2017-12-07
BRPI1010908A2 (pt) 2016-03-15
MX2011011958A (es) 2012-02-13
US20160145693A1 (en) 2016-05-26
IL216296A0 (en) 2012-01-31
KR20120034649A (ko) 2012-04-12
IL216299A0 (en) 2012-01-31
BRPI1011025A2 (pt) 2016-03-29
AU2010247750A1 (en) 2011-12-15
JP2018021064A (ja) 2018-02-08
KR20180018833A (ko) 2018-02-21
AU2010247755A1 (en) 2011-12-15
SG10201402289VA (en) 2014-07-30
JP2012526829A (ja) 2012-11-01
KR20120060945A (ko) 2012-06-12
AU2010247734B2 (en) 2016-04-14
JP2012526554A (ja) 2012-11-01
US10519504B2 (en) 2019-12-31
AU2016269471A1 (en) 2016-12-22
KR20180056816A (ko) 2018-05-29
EA201101521A1 (ru) 2012-09-28
CA2763347A1 (en) 2010-11-18
US20170137879A1 (en) 2017-05-18
WO2010132507A2 (en) 2010-11-18
JP2017018134A (ja) 2017-01-26
US20150023940A1 (en) 2015-01-22
BRPI1010648A2 (pt) 2016-03-15
CN102481271A (zh) 2012-05-30
SG175993A1 (en) 2011-12-29
EP2430455A4 (en) 2013-09-04
WO2010132440A2 (en) 2010-11-18
EP2429513A4 (en) 2013-08-14
MX357528B (es) 2018-07-13
EP2430194A4 (en) 2013-09-04
CN102482713B (zh) 2017-06-30
AU2010247755B2 (en) 2016-09-15
JP2018048125A (ja) 2018-03-29
EA201101522A1 (ru) 2012-09-28
CA2763347C (en) 2021-11-23
EA201101520A1 (ru) 2012-09-28
US11028446B2 (en) 2021-06-08
KR20120088555A (ko) 2012-08-08
EP2429511B1 (en) 2019-02-20
EP2429511A4 (en) 2013-08-28
EP2430194A2 (en) 2012-03-21
WO2010132486A2 (en) 2010-11-18
JP5903734B2 (ja) 2016-04-13
EP2429511A2 (en) 2012-03-21
CA2762213A1 (en) 2010-11-18
EP2429512A4 (en) 2013-07-31
US9896731B2 (en) 2018-02-20
CN104825429A (zh) 2015-08-12
KR20140014390A (ko) 2014-02-06
AU2016222422A1 (en) 2016-09-22
US20110123987A1 (en) 2011-05-26
WO2010132507A3 (en) 2011-03-31
WO2010132486A3 (en) 2011-03-03
MX345044B (es) 2017-01-16
JP2012526828A (ja) 2012-11-01
CA2763336C (en) 2018-10-30
MX351083B (es) 2017-09-29
JP2016023190A (ja) 2016-02-08
CA2763325A1 (en) 2010-11-18
JP2017074038A (ja) 2017-04-20
AU2010247750B2 (en) 2016-09-22
WO2010132479A2 (en) 2010-11-18
KR101829201B1 (ko) 2018-02-19
CA2761717A1 (en) 2010-11-18
SG10201402291QA (en) 2014-07-30
US20180334721A1 (en) 2018-11-22
US20110123986A1 (en) 2011-05-26
WO2010132502A3 (en) 2011-04-21
MX2011011940A (es) 2012-06-25
US20220081720A1 (en) 2022-03-17
BRPI1010827A2 (pt) 2019-09-24
JP2016023189A (ja) 2016-02-08
US10351915B2 (en) 2019-07-16
US20190010554A1 (en) 2019-01-10
JP5903735B2 (ja) 2016-04-13
JP2015199746A (ja) 2015-11-12
AU2010247761A1 (en) 2011-12-15
EA034552B1 (ru) 2020-02-19
US20110110914A1 (en) 2011-05-12
AU2010247734A1 (en) 2011-12-15
AU2010247800A1 (en) 2011-12-15
SG175994A1 (en) 2011-12-29
MX349796B (es) 2017-08-11
JP6081195B2 (ja) 2017-02-15
CN102483419B (zh) 2017-12-15
MX2011011947A (es) 2012-01-30
IL216296B (en) 2020-06-30
JP6169846B2 (ja) 2017-07-26
CN102481269A (zh) 2012-05-30
CN105287449A (zh) 2016-02-03
EA201101523A1 (ru) 2012-10-30
WO2010132440A3 (en) 2011-04-07
EP2429513A2 (en) 2012-03-21
CN102481269B (zh) 2015-10-07
EP2430455A2 (en) 2012-03-21
US20200157630A1 (en) 2020-05-21
EP2429512A2 (en) 2012-03-21
SG175991A1 (en) 2011-12-29
US9205064B2 (en) 2015-12-08
US20210002725A1 (en) 2021-01-07
SG10201402287TA (en) 2014-07-30
SG10201402288RA (en) 2014-07-30
IL216297A0 (en) 2012-01-31
US20110027247A1 (en) 2011-02-03
CA2763336A1 (en) 2010-11-18
IL216298A0 (en) 2012-01-31
JP2012526555A (ja) 2012-11-01
CN102482713A (zh) 2012-05-30
SG175996A1 (en) 2011-12-29
IL216295A0 (en) 2012-01-31
SG175992A1 (en) 2011-12-29
KR101860294B1 (ko) 2018-07-02
JP2012526824A (ja) 2012-11-01
WO2010132502A2 (en) 2010-11-18
MX2011011942A (es) 2011-12-06
WO2010132479A3 (en) 2011-03-31
SG10201402293SA (en) 2014-08-28
EA201101519A1 (ru) 2012-10-30
US20110020312A1 (en) 2011-01-27
CN102483419A (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
EA023913B1 (ru) Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
Morris et al. Increasing Nrf2 activity as a treatment approach in neuropsychiatry
Maiese New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR
Yao et al. On the nutritional and therapeutic effects of ketone body d-β-hydroxybutyrate
Liang et al. Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling
Lee et al. Nutritional supplements and their effect on glucose control
Lee et al. Hepatoprotective effect of esculetin on ethanol-induced liver injury in human HepG2 cells and C57BL/6J mice
Supruniuk et al. Branched chain amino acids—friend or foe in the control of energy substrate turnover and insulin sensitivity?
Fink et al. Effect of mitoquinone (Mito-Q) on neuropathic endpoints in an obese and type 2 diabetic rat model
Qin et al. Gluconolactone alleviates myocardial ischemia/reperfusion injury and arrhythmias via activating PKCε/extracellular signal-regulated kinase signaling
Xu et al. Tanshinone IIA pretreatment attenuates ischemia/reperfusion-induced renal injury
Kwon et al. Antioxidant and antifatigue effect of a standardized fraction (HemoHIM) from Angelica gigas, Cnidium officinale, and Paeonia lactiflora
Feng et al. Atorvastatin prevents endoplasmic reticulum stress-mediated apoptosis via the Nrf2/HO-1 signaling pathway in TBI mice
Schiuma et al. Nicotinamide Adenine Dinucleotide: The Redox Sensor in Aging-Related Disorders
Ye et al. Mitochondrial energy metabolism in diabetic cardiomyopathy: Physiological adaption, pathogenesis, and therapeutic targets
Cardinali et al. Melatonin as a Chronobiotic and Cytoprotector in Non-communicable Diseases: More than an Antioxidant
Marasini et al. Neuroprotective approaches for brain injury after cardiac arrest: Current trends and prospective avenues
Chen et al. Hydrogen-rich saline may be an effective and specific novel treatment for osteoradionecrosis of the jaw
ES2628295T3 (es) Sulforafano para tratar o reducir la resistencia a la insulina del hígado
Shahouzehi et al. Concomitant Administration of L-carnitine and Performing HighIntensity Interval Training Effects on the Genes Involved in Mitochondrial Fusion and Apoptosis in Rat Liver.
Hu et al. The Molecular Biological Mechanism of Hydrogen Therapy and Its Application in Spinal Cord Injury
Zhang et al. Da‐Chuan‐Xiong decoction ameliorates sodium sensitivity and plasma norepinephrine via attenuation of brain oxidative stress in the DOCA‐salt hypertensive rats
LeBaron et al. Effects of an H2-infused, nitric oxide-producing functional beverage on exercise and cognitive performance
Zhou et al. Protective effect of pretreatment with propofol against tumor necrosis factor-α-induced hepatic insulin resistance
Baghcheghi et al. Thymoquinone improved redox homeostasis in the heart and aorta of hypothyroid rats

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU